Covered recipient · General Payments record
JILL M POWERS
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$517.49
- Reported across 26 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $277.24 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $45.00 | 3 |
| ABBVIE INC. | $35.92 | 2 |
| PFIZER INC. | $35.82 | 2 |
| Nevro Corp. | $33.36 | 1 |
| Janssen Pharmaceuticals, Inc | $26.73 | 1 |
| Astellas Pharma US Inc | $23.35 | 1 |
| Stryker Corporation | $17.45 | 1 |
| Abbott Laboratories | $16.48 | 1 |
| Lilly USA, LLC | $14.78 | 1 |
| Xeris Pharmaceuticals, Inc. | $14.35 | 1 |
| Amgen Inc. | $14.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $16.48 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125332698 | CMS |
| ABBVIE INC. | $21.43 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105304993 | CMS |
| ABBVIE INC. | $14.49 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105304997 | CMS |
| Amgen Inc. | $14.00 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117356652 | CMS |
| Astellas Pharma US Inc | $23.35 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139291208 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.16 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104278703 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.96 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105626497 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.88 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105273799 | CMS |
| Janssen Pharmaceuticals, Inc | $26.73 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1077999330 | CMS |
| Lilly USA, LLC | $14.78 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135049430 | CMS |
| Nevro Corp. | $33.36 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130754383 | CMS |
| PFIZER INC. | $17.77 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131160265 | CMS |
| PFIZER INC. | $18.05 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131152892 | CMS |
| Stryker Corporation | $17.45 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119948830 | CMS |
| Xeris Pharmaceuticals, Inc. | $14.35 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144598884 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.